SCHEMBL17660347

SCHEMBL17660347

CCc1ccc(-c2ccnc3[nH]c(-c4ccc(OC)cc4)nc23)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 5/20 0.43
▸ TGFBR1 P36897 1/20 0.43
▸ MAPK14 Q16539 2/20 0.43
▸ CCNB2 O95067 6/20 0.40
▸ CDK1 P06493 6/20 0.40
▸ CCNB1 P14635 6/20 0.40
▸ CCNB3 Q8WWL7 6/20 0.40
▸ GSK3A P49840 5/20 0.40
▸ GSK3B P49841 5/20 0.40
▸ CDK5 Q00535 4/20 0.40
▸ CDK5R1 Q15078 4/20 0.40
▸ CCNE1 P24864 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ ZAP70 P43403 1/20 0.39
▸ PTK2B Q14289 1/20 0.39
▸ RPS6KA3 P51812 1/20 0.38
▸ AURKA O14965 1/20 0.38
▸ RIPK1 Q13546 1/20 0.38
▸ TNKS O95271 2/20 0.38
▸ PARP1 P09874 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17645984 0.91 MAPK14 (0.42) BTKTGFBR1MAPK14CCNB2CDK1
SCHEMBL17646003 0.91 MAPK14 (0.42) BTKTGFBR1MAPK14CCNB2CDK1
SCHEMBL17660348 0.90 DHODH (0.45) CCNB2CDK1CCNB1CCNB3GSK3A
SCHEMBL17660350 0.88 MAPK14 (0.41) BTKMAPK14PTGDR2
SCHEMBL17664691 0.84 BTK (0.47) BTK
SCHEMBL17645914 0.81 BTK (0.62) BTK
SCHEMBL17646039 0.81 MGAT2 (0.47) BTKMAPK14CCNB2CDK1CCNB1
SCHEMBL17646013 0.81 MGAT2 (0.47) BTKMAPK14CCNB2CDK1CCNB1
SCHEMBL17645780 0.80 BTK (0.42) BTKTGFBR1MAPK14CCNB2CDK1
SCHEMBL17660360 0.80 BTK (0.47) BTKMAPK14CCNB2CDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160096834-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2016-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160096834-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF BTK, SYK, LYN BTK 1/4885TGFBR1 3784/4885MAPK14 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback